Ecuador Approves a New Essential-Medicines List With 512 Active Ingredients

Ecuador has approved a new national list defining the essential medicines to be available in the country’s National Health System.

The Consejo Nacional de Salud (CONASA) approved the new Cuadro Nacional de Medicamentos Básicos (CNMB) on August 5, 2026. The twelfth revision includes 512 active ingredients, up from 494 in the eleventh revision that has governed the list since 2023.

What changes

The revision includes changes to doses, product exclusions, and expanded indications for use. Health authorities said the broader list is intended to support cancer patients and people with other conditions that had been underserved.

The catalog is not effective simply because it was approved. The 512 active ingredients are expected to enter into force during 2026, after the document is officially published in the Registro Oficial.

That creates an important distinction for patients and families. An item appearing on the approved list does not by itself confirm that every hospital or pharmacy already has it in stock. The implementation step still matters.

A second policy change

Authorities also approved the National Health Human Resources Policy for 2026–2030. The policy is intended to regulate and strengthen planning, management, and academic training for medical personnel, with the stated aim of supporting dignified working conditions and implementation of the health-care career.

The health minister, Juan Carlos Aveiga, described the medicines-list approval as progress toward a fairer system, better use of public resources, and a more sustainable health network.

What expats should watch

Foreign residents who use Ecuador’s public system, private providers, or insurance should watch three separate steps: official publication, operational implementation, and actual availability. The list can change what the system is supposed to cover, but practical access still depends on the facility, the condition being treated, the prescription, and local inventory.

For a patient managing an ongoing condition, keep a current medication list and ask the provider whether the relevant active ingredient is covered under the new revision once it is published. The policy is meaningful, but the useful test will be whether the expanded catalog reaches patients consistently.